- University of Pennsylvania’s School of Veterinary Medicine to Evaluate New Gastrointestinal Panel Using LexaGene’s MiQLab System
- According to Dr. Regan, GI issues such as acute diarrhea are the most common reason why owners bring their pets to the vet
- The GI panel screens for five bacteria, 11 toxins genes and four protozoans
- LexaGene has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers
- LexaGene Holdings (LXG) is up over 9 per cent, trading at C$0.12 at 10:52 am EST
LexaGene Holdings (LXG) has begun evaluating a gastrointestinal (GI) pathogen panel at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet).
Dr. Jack Regan, LexaGene’s Founder and CEO, stated, “GI issues such as acute diarrhea are the most common reason why companion animal owners bring their pet to see a veterinarian.”
“Rapidly diagnosing GI issues caused by pathogenic bacteria, protozoans, and viruses are difficult with standard microscopy, and rapid tests are either lacking or poor in sensitivity,” added Dr. Regan.
Dr. Nathan Walsh, LexaGene’s VP of Applications and Bioinformatics, stated, “Our GI panel screens for five bacteria, 11 toxins genes commonly associated with acute diarrhea, four protozoans, and a virus family that includes common GI viruses.”
“[such] pathogens and toxins are commonly responsible for gastrointestinal distress, and knowing the identity of the pathogen and toxin genes helps guide treatment decisions,” concluded Dr. Walsh.
The MiQLab GI Pathogen Panel screens for the most common five bacteria, including campylobacter, clostridium difficile, clostridium perfringens, escherichia coli, and salmonella.
LexaGene has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers. The System is designed for on-site usage and uses real-time PCR chemistry.
LexaGene Holdings (LXG) is up over 9 per cent, trading at C$0.12 at 10:52 am EST.
